AviadoBio develop transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders.
AviadoBio specialises in researching and developing potential new treatments for two extremely debilitating diseases: Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). FTD is one of most common forms of dementia in individuals under the age of 65 after Alzheimer’s disease. Amyotrophic lateral sclerosis (ALS), which is more commonly known as Motor Neuron Disease (MND), or Lou Gehrig’s disease, is a devastating neurodegenerative disease characterized by the degeneration of upper and lower motor neurons in the brain and spinal cord.
“QMB Innovation Centre’s world-class facilities fulfil all our research needs and form a critical part of AviadoBio’s infrastructure as a young dynamic biotech. It is a fantastic space with state-of-the-art laboratories, and we are thrilled to be situated in the heart of London alongside a hotbed of innovative companies.”
Lisa Deschamps, Chief Executive Officer, AviadoBio
& MEETING ROOMS